TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study
Brief Summary: This is a study to assess the efficacy and safety of the addition of cetuximab to the combined regimen of capecitabine, oxaliplatin and bevacizumab in patients with previously untreated advanced colorectal carcinoma. It is an open, comparative study, comparing the effects of capecitabine, oxaliplatin and bevacizumab to those of the same regimen plus cetuximab.

Seven hundred fifty patients will be included. Treatment will continue until disease progression or serious toxicity and follow up will continue until death. It is anticipated that the addition of cetuximab will lead to an increase in progression free survival.


Options:
A: Arm Label: 1Capecitabine + bevacizumab + oxaliplatin + cetuximab; Type: EXPERIMENTAL; Interventions: Drug: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab | Arm Label: 21Capecitabine + bevacizumab + oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 21Capecitabine + bevacizumab + oxaliplatin | Intervention Type: DRUG; Name: 21Capecitabine + bevacizumab + oxaliplatin; Assigned to Arm(s): 21Capecitabine + bevacizumab + oxaliplatin | Intervention Type: DRUG; Name: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab; Assigned to Arm(s): 1Capecitabine + bevacizumab + oxaliplatin + cetuximab
B: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care
C: Arm Label: Cetuximab Plus FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Arm Label: FOLFIRI Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Cetuximab Plus FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); Assigned to Arm(s): Cetuximab Plus FOLFIRI, FOLFIRI Alone
D: Arm Label: bevacizumab alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: Bevacizumab + erlotinib; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, erlotinib | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab alone | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): Bevacizumab + erlotinib

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration in Critically Ill Patients With Acute Renal Failure: A Randomized Clinical Trial
Brief Summary: The purpose of this study is to compare citrate regional anticoagulation with systemic heparinization in continuous venovenous hemofiltration. The investigators' hypothesis is, that regional citrate anticoagulation with replacement solution containing trisodium citrate, will be associated with lower mortality and less bleeding complications compared to heparin, with also a better filter survival.


Options:
A: Arm Label: Prismocitrate 18; Type: EXPERIMENTAL; Interventions: Drug: Prismocitrate 18 | Arm Label: No Regional Anticoagulation of CRRT Circuit; Type: ACTIVE_COMPARATOR; Interventions: Other: No Anticoagulation | Intervention Type: DRUG; Name: Prismocitrate 18; Assigned to Arm(s): Prismocitrate 18 | Intervention Type: OTHER; Name: No Anticoagulation; Assigned to Arm(s): No Regional Anticoagulation of CRRT Circuit
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: High cut-off (super high flux) polyamide membrane | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard polyamide high flux membrane | Intervention Type: DEVICE; Name: Standard polyamide high flux membrane; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: High cut-off (super high flux) polyamide membrane; Assigned to Arm(s): 1
C: Arm Label: heparin; Type: ACTIVE_COMPARATOR; Interventions: Other: regional anticoagulation with citrate | Arm Label: Citrate; Type: ACTIVE_COMPARATOR; Interventions: Other: HfCitPre | Intervention Type: OTHER; Name: regional anticoagulation with citrate; Assigned to Arm(s): heparin | Intervention Type: OTHER; Name: HfCitPre; Assigned to Arm(s): Citrate
D: Arm Label: citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: trisodium citrate | Arm Label: nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparin | Intervention Type: DRUG; Name: trisodium citrate; Assigned to Arm(s): citrate | Intervention Type: DRUG; Name: nadroparin; Assigned to Arm(s): nadroparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration in Critically Ill Patients With Acute Renal Failure: A Randomized Clinical Trial
Brief Summary: The purpose of this study is to compare citrate regional anticoagulation with systemic heparinization in continuous venovenous hemofiltration. The investigators' hypothesis is, that regional citrate anticoagulation with replacement solution containing trisodium citrate, will be associated with lower mortality and less bleeding complications compared to heparin, with also a better filter survival.


Options:
A: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
B: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
C: Arm Label: heparin; Type: ACTIVE_COMPARATOR; Interventions: Other: regional anticoagulation with citrate | Arm Label: Citrate; Type: ACTIVE_COMPARATOR; Interventions: Other: HfCitPre | Intervention Type: OTHER; Name: regional anticoagulation with citrate; Assigned to Arm(s): heparin | Intervention Type: OTHER; Name: HfCitPre; Assigned to Arm(s): Citrate
D: Arm Label: citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: trisodium citrate | Arm Label: nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparin | Intervention Type: DRUG; Name: trisodium citrate; Assigned to Arm(s): citrate | Intervention Type: DRUG; Name: nadroparin; Assigned to Arm(s): nadroparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration in Critically Ill Patients With Acute Renal Failure: A Randomized Clinical Trial
Brief Summary: The purpose of this study is to compare citrate regional anticoagulation with systemic heparinization in continuous venovenous hemofiltration. The investigators' hypothesis is, that regional citrate anticoagulation with replacement solution containing trisodium citrate, will be associated with lower mortality and less bleeding complications compared to heparin, with also a better filter survival.


Options:
A: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2
B: Arm Label: AKI requring CRRT and use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with regional citrate anticoagulation | Arm Label: AKI requring CRRT and not use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with no anticoagulation or heparin | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with regional citrate anticoagulation; Assigned to Arm(s): AKI requring CRRT and use regional citrate anticoagulation | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with no anticoagulation or heparin; Assigned to Arm(s): AKI requring CRRT and not use regional citrate anticoagulation
C: Arm Label: Heparin lock; Type: PLACEBO_COMPARATOR; Interventions: Drug: unfractionated heparin | Arm Label: Citrate lock; Type: EXPERIMENTAL; Interventions: Drug: Citrate 4% | Intervention Type: DRUG; Name: Citrate 4%; Assigned to Arm(s): Citrate lock | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): Heparin lock
D: Arm Label: heparin; Type: ACTIVE_COMPARATOR; Interventions: Other: regional anticoagulation with citrate | Arm Label: Citrate; Type: ACTIVE_COMPARATOR; Interventions: Other: HfCitPre | Intervention Type: OTHER; Name: regional anticoagulation with citrate; Assigned to Arm(s): heparin | Intervention Type: OTHER; Name: HfCitPre; Assigned to Arm(s): Citrate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Placebo Controlled, Double Blind Trial of Metformin in Obese Adolescents.
Brief Summary: This study will determine if the drug metformin, coupled with diet and exercise counseling, will help obese adolescents lose weight.


Options:
A: Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): N/A
B: Arm Label: caffeine and ephedrine; Type: EXPERIMENTAL; Interventions: Drug: caffeine and ephedrine | Arm Label: leptin A; Type: EXPERIMENTAL; Interventions: Drug: Leptin A | Arm Label: caffeine, ephedrine, and leptin A; Type: EXPERIMENTAL; Interventions: Drug: caffeine, ephedrine, and leptin A | Intervention Type: DRUG; Name: caffeine and ephedrine; Assigned to Arm(s): caffeine and ephedrine | Intervention Type: DRUG; Name: Leptin A; Assigned to Arm(s): leptin A | Intervention Type: DRUG; Name: caffeine, ephedrine, and leptin A; Assigned to Arm(s): caffeine, ephedrine, and leptin A
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: glucophage XR; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women
Brief Summary: We aim to evaluate whether IPT in pregnancy provides any additional benefit to the protection afforded by ITNs.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cotrimoxazole | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Cotrimoxazole | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: Cotrimoxazole; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine; Assigned to Arm(s): 2, 4
B: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine (Fansidar); Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ITNs; Assigned to Arm(s): N/A
C: Arm Label: IPTp-DP; Type: EXPERIMENTAL; Interventions: Drug: IPTp-DP | Arm Label: ISTp-DP; Type: EXPERIMENTAL; Interventions: Drug: ISTp-DP | Arm Label: IPTp-SP; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPTp-SP | Intervention Type: DRUG; Name: IPTp-SP; Assigned to Arm(s): IPTp-SP | Intervention Type: DRUG; Name: IPTp-DP; Assigned to Arm(s): IPTp-DP | Intervention Type: DRUG; Name: ISTp-DP; Assigned to Arm(s): ISTp-DP
D: Arm Label: Mefloquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine | Arm Label: Sulphadoxine-Pyrimethamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-Pyrimethamine | Intervention Type: DRUG; Name: Mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Sulphadoxine-Pyrimethamine; Assigned to Arm(s): Sulphadoxine-Pyrimethamine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women
Brief Summary: We aim to evaluate whether IPT in pregnancy provides any additional benefit to the protection afforded by ITNs.


Options:
A: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine / mefloquine; Assigned to Arm(s): N/A
B: Arm Label: DHAPQ; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Arm Label: MQAS; Type: EXPERIMENTAL; Interventions: Drug: Artesunate-mefloquine | Arm Label: AQAS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate-amodiaquine | Arm Label: AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): DHAPQ | Intervention Type: DRUG; Name: Artesunate-mefloquine; Assigned to Arm(s): MQAS | Intervention Type: DRUG; Name: Artesunate-amodiaquine; Assigned to Arm(s): AQAS | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): AL
C: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine (Fansidar); Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ITNs; Assigned to Arm(s): N/A
D: Arm Label: Trial 1: IPTp-SP+LLITNs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine | Arm Label: Trial 1: IPTp-MQ (full dose) + LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (full dose) | Arm Label: Trial 1: IPTp-MQ (split dose)+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (split dose) | Arm Label: Trial 2: CTX+IPTp-Placebo+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Trial 2: CTX + IPTp-MQ+ LLITNs; Type: EXPERIMENTAL; Interventions: Drug: mefloquine | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): Trial 1: IPTp-SP+LLITNs | Intervention Type: DRUG; Name: Mefloquine (full dose); Assigned to Arm(s): Trial 1: IPTp-MQ (full dose) + LLITNs | Intervention Type: DRUG; Name: Mefloquine (split dose); Assigned to Arm(s): Trial 1: IPTp-MQ (split dose)+LLITNs | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Trial 2: CTX+IPTp-Placebo+LLITNs | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Trial 2: CTX + IPTp-MQ+ LLITNs

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women
Brief Summary: We aim to evaluate whether IPT in pregnancy provides any additional benefit to the protection afforded by ITNs.


Options:
A: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine / mefloquine; Assigned to Arm(s): N/A
B: Arm Label: DHAPQ; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Arm Label: MQAS; Type: EXPERIMENTAL; Interventions: Drug: Artesunate-mefloquine | Arm Label: AQAS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate-amodiaquine | Arm Label: AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): DHAPQ | Intervention Type: DRUG; Name: Artesunate-mefloquine; Assigned to Arm(s): MQAS | Intervention Type: DRUG; Name: Artesunate-amodiaquine; Assigned to Arm(s): AQAS | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): AL
C: Arm Label: Trial 1: IPTp-SP+LLITNs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine | Arm Label: Trial 1: IPTp-MQ (full dose) + LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (full dose) | Arm Label: Trial 1: IPTp-MQ (split dose)+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (split dose) | Arm Label: Trial 2: CTX+IPTp-Placebo+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Trial 2: CTX + IPTp-MQ+ LLITNs; Type: EXPERIMENTAL; Interventions: Drug: mefloquine | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): Trial 1: IPTp-SP+LLITNs | Intervention Type: DRUG; Name: Mefloquine (full dose); Assigned to Arm(s): Trial 1: IPTp-MQ (full dose) + LLITNs | Intervention Type: DRUG; Name: Mefloquine (split dose); Assigned to Arm(s): Trial 1: IPTp-MQ (split dose)+LLITNs | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Trial 2: CTX+IPTp-Placebo+LLITNs | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Trial 2: CTX + IPTp-MQ+ LLITNs
D: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine (Fansidar); Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ITNs; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women
Brief Summary: We aim to evaluate whether IPT in pregnancy provides any additional benefit to the protection afforded by ITNs.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine treatment twice during pregnancy | Arm Label: Monthly SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine at 4-week intervals | Arm Label: AZI-SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine treatment twice during pregnancy; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine at 4-week intervals; Assigned to Arm(s): Monthly SP | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice; Assigned to Arm(s): AZI-SP
B: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine (Fansidar); Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ITNs; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine, amodiaquine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine / mefloquine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This is a randimized clinical trial comparing the effect of supervised Nordic walking versus unsupervised Nordic walking versus advice to stay active


Options:
A: Arm Label: Community-based pain self-management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community-based pain self-management | Arm Label: Clinic-based pain self-management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic-based pain self-management | Intervention Type: BEHAVIORAL; Name: Community-based pain self-management; Assigned to Arm(s): Community-based pain self-management | Intervention Type: BEHAVIORAL; Name: Clinic-based pain self-management; Assigned to Arm(s): Clinic-based pain self-management
B: Arm Label: BB; Type: ACTIVE_COMPARATOR; Interventions: Other: Mild, Other: Mild vs. NC | Arm Label: BB+A; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Mild, Other: Mild vs. NC, Other: Moderate vs. NC | Arm Label: DBC; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Moderate vs. NC | Arm Label: PMU; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Moderate vs. NC | Arm Label: NC; Type: PLACEBO_COMPARATOR; Interventions: Other: Mild vs. NC, Other: Moderate vs. NC | Intervention Type: OTHER; Name: Moderate; Assigned to Arm(s): BB+A, DBC, PMU | Intervention Type: OTHER; Name: Mild; Assigned to Arm(s): BB, BB+A | Intervention Type: OTHER; Name: Mild vs. NC; Assigned to Arm(s): BB, BB+A, NC | Intervention Type: OTHER; Name: Moderate vs. NC; Assigned to Arm(s): BB+A, DBC, NC, PMU
C: Arm Label: Motor Control Exercise Plus Patient Education; Type: EXPERIMENTAL; Interventions: Behavioral: Motor Control Exercise, Behavioral: Patient Education | Arm Label: Motor Control Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Motor Control Exercise | Arm Label: Patient Education; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Education | Intervention Type: BEHAVIORAL; Name: Motor Control Exercise; Assigned to Arm(s): Motor Control Exercise, Motor Control Exercise Plus Patient Education | Intervention Type: BEHAVIORAL; Name: Patient Education; Assigned to Arm(s): Motor Control Exercise Plus Patient Education, Patient Education
D: Intervention Type: BEHAVIORAL; Name: Supervised Nordic Walking; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Unsupervised Nordic Walking; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Advice to stay active; Assigned to Arm(s): N/A

Answer: D